Abstract
Two different doses of quinupristin/dalfopristin were compared with intravenous vancomycin with regard to the efficacy and safety in the treatment of catheter-related staphylococcal bacteremia. A total of 39 patients were enrolled from 13 centers. For all treated patients with a baseline pathogen, outcome was comparable for all antibiotic study regimens. Discontinuation of the antibiotic for an adverse clinical event occurred in 12% of patients receiving quinupristin/dalfopristin and in 15% of those receiving vancomycin. Quinupristin/dalfopristin may have the potential to serve as an alternative agent in the treatment of catheter-related staphylococcal bacteremia. However, larger prospective randomized trials are required.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raad, I., Bompart, F. & Hachem, R. Prospective, Randomized Dose-Ranging Open Phase II Pilot Study of Quinupristin/Dalfopristin versus Vancomycin in the Treatment of Catheter-Related Staphylococcal Bacteremia. EJCMID 18, 199–202 (1999). https://doi.org/10.1007/s100960050258
Issue Date:
DOI: https://doi.org/10.1007/s100960050258